| Identification | |
| Name: | Erlotinib hydrochloride |
| Synonyms: | 4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI);6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride;CP358774;4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1);OSI 774;Tarceva;[6,7-Bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride;Erlotinib HCl;Erlotinib hydrochloride and Intermediate; |
| CAS: | 183319-69-9 |
| Molecular Formula: | C22H24ClN3O4 |
| Molecular Weight: | 429.9 |
| InChI: | InChI=1/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H |
| Molecular Structure: |  |
| Properties | |
| Density: | g/cm3 |
| Appearance: | White or off-white powder |
| Usage: | Erlotinib hydrochloride (CAS NO.183319-69-9) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. |
| Safety Data | |
 |
|
